Provided by Tiger Trade Technology Pte. Ltd.

Tempest Therapeutics Inc.

2.40
+0.17007.62%
Post-market: 2.470.0700+2.92%19:52 EST
Volume:82.38K
Turnover:197.90K
Market Cap:11.83M
PE:-0.24
High:2.50
Open:2.21
Low:2.21
Close:2.23
52wk High:12.48
52wk Low:2.17
Shares:4.93M
Float Shares:4.65M
Volume Ratio:0.25
T/O Rate:1.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.1030
EPS(LYR):-19.4955
ROE:-405.03%
ROA:-89.32%
PB:1.86
PE(LYR):-0.12

Loading ...

Tempest Therapeutics Inc. Files Initial Statement of Beneficial Ownership for CEO and President Matthew Angel

Reuters
·
7 hours ago

Tempest Therapeutics kündigt Privatplatzierung und unregistrierten Aktienverkauf an

Reuters
·
7 hours ago

BRIEF-Tempest Announces Closing Of Strategic Acquisition Of Dual-Targeting Car-T Assets

Reuters
·
Feb 05

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

THOMSON REUTERS
·
Feb 05

Tempest Therapeutics Faces Nasdaq Delisting Notice Over Missed Annual Meeting Deadline

Reuters
·
Jan 10

Tempest Therapeutics Inc. Announces Date for Upcoming Annual Stockholder Meeting

Reuters
·
Dec 03, 2025

BRIEF-Tempest Announces Closing Of Up To $8.35 Million Registered Direct Offering Of Common Stock And Concurrent Private Placement Of Warrants Priced At-The-Market Under Nasdaq Rules

Reuters
·
Nov 27, 2025

Tempest Therapeutics Raises $8.35 Million Through Registered Direct Offering and Private Placement

Reuters
·
Nov 27, 2025

Top Midday Decliners

MT Newswires Live
·
Nov 26, 2025

Tempest Therapeutics Announces Private Placement of Unregistered Warrants for Up to $4.1 Million

Reuters
·
Nov 25, 2025

Tempest Announces up to $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Nov 25, 2025

Tempest Therapeutics Inc - Entered Definitive Agreement for Purchase & Sale of 1.2 Mln Common Shares at $3.625 per Share

THOMSON REUTERS
·
Nov 25, 2025

Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results

Benzinga
·
Nov 20, 2025

Tempest Therapeutics Q3 EPS USD -0.79

Reuters
·
Nov 20, 2025

Why Tempest Therapeutics (TPST) Stock Is Down 45% Today

Benzinga
·
Nov 20, 2025

Tempest Therapeutics Announces Private Placement of Unregistered Shares

Reuters
·
Nov 19, 2025

Tempest Therapeutics Inc - Matt Angel to Become President and CEO

THOMSON REUTERS
·
Nov 19, 2025

Tempest Announces Strategic Acquisition of New Dual-Car T Programs From Factor With Simultaneous Runway Extension Projected to Mid 2027

THOMSON REUTERS
·
Nov 19, 2025

Tempest Therapeutics Inc - Investment Commitment to Support Operations to Mid 2027

THOMSON REUTERS
·
Nov 19, 2025

Tempest Therapeutics Inc: Stephen Brady to Assume Role of Chairman of Board Upon Closing of Acquisition

THOMSON REUTERS
·
Nov 19, 2025